Latest Conference Articles

The rates of adverse events was similar across all 4 indications in comparison to the placebo group.

Hypertension rates were low in both ulcerative colitis and multiple sclerosis patients treated with ozanimod, regardless of concurrent SNRI/SSRI use.

Investigators propose oral treprostinil be considered when treating patients with pulmonary arterial hypertension.

The retina field is equipped with ideal therapy and research informing implementation. Now it needs greater patient buy-in.

Assessment from a patient survey showed an association between increased rates of injection treatment and increased restriction on usual activity for patients.

Rishi P. Singh, MD, discusses new VISTA/VIVID data showing what really influences a patients' likelihood and time to DME resolution when treated with aflibercept.

Theodore Leng, MD, MS, defines the trends of patient discontinuation, and how direct caregivers may help to reduce risk of losing patients.

Arshad Khanani, MD, MA, explains how new measures made available to ophthalmology will help address a quickly growing patient population.

There were no episode of gastrointestinal bleeding, transfusion of packed red blood cells, or octreotide infusions observed.

Investigators collected data from several studies which tested the efficacy of the ointment on pediatric populations affected by atopic dermatitis and their families.

Veeral S. Sheth, MD, MBA, discusses what ophthalmologists will need to learn about PDS application for patients with AMD.

Theodore Leng, MD, MS, discusses new findings based on IRIS registry data showing long-term discontinuation trends in patients.

Dr. Mehta talks about rheumatologic testing, joint examinations, and the great relationships he gets to develop with his patients.

An approval may be pending for the unique delivery system. An expert explains its benefit for nAMD patients and physicians alike.

Dr. Ponder continued his discussion on technology use in pediatric T1D care, focusing on a multidisciplinary care angle and different concepts in treatment.

Investigators reported that machine learning was non-invasive and accessible to a large array of clinicians, and could help prevent infants from developing atopic dermatitis.

Dr. Carbone presented about autism management during the 2021 AAP virtual conference.

Dr. Ponder discusses the importance of both clinician and patient learning about new diabetic technologies, focusing on their utility and limitations in the care process.

Dr. Chan said clinical practice guidelines ideally cover about 75% of patients with ADHD.

A retina care team highlighted positive patient feedback from their makeshift system; could it be a long-term solution?

A greater rate of intravitreal injection appointments were delayed last year, causing worse patient scores in BCVA and OTC.

New cohort analyses show endophthalmitis was not significantly reduced in treatment encounters where both physicians and patients were masked.

Dr. Bujoreanu explains how treatments like Cognitive Behavioral Therapy can have a positive impact on chronic pain in pediatric patients.

Dr. Maguiness speaks of new forms of tinea capitis not traditionally seen in the United States, as well as common practices shared between parents and clinicians for the management of several hair and nail disorders.

During this video interview, Dr. Bujoreanu expresses the importance of the multidisciplinary approach of the biopsychosocial model in chronic pain treatment.

Children are now screened for autism at 18 and 24 months.

Dr. Hawryluk noted that acne is estimated to affect 35%-95% of pediatric patients worldwide, though proper diagnosis and treatment of this dermatological condition is possible.

Dr. Owotomo and fellow investigators evaluated 1298 children from the Washington DC area and found that called for greater asthma care by pulmonologists and allergists alike.

Findings from YOSEMITE and RHINE show a significant rate of patients on faricimab were able to extend their dosing to once every 16 weeks after a year of therapy.

Positive phase 1 and 2 findings support an ongoing efficacy assessment of the Ref-1 inhibitor for diabetic retinopathy and diabetic macular edema.